# Nuclivision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuclivision

- Industry: Medical Devices & Equipment
- Headquarters: Ghent, Belgium
- Website: www.nuclivision.com
- Total disclosed funding: $2.3M
- Latest round: Seed (May 7, 2025)
- Investors on record: 3

## About

Nuclivision BV is a technology firm dedicated to providing advanced software solutions tailored for the nuclear medicine sector, enhancing diagnostic workflows and improving patient outcomes through innovative applications.Founded in 2022 in Ghent, Belgium, Nuclivision BV focuses on developing specialized software solutions for the nuclear medicine field. The company recently pivoted its operations to concentrate on artificial intelligence applications in PET imaging. With only 1 total deal reported, their most recent deal occurred on April 24, 2025. In this funding round, they raised EUR 5 million led by HERAN Partners, Imec.xpand, and LUMO Labs BV, marking the total amount raised at EUR 5 million.  There is no mention of subsidiaries or parent companies at this time.Nuclivision specializes in advanced software solutions for the nuclear medicine field, focusing on enhancing the workflow of physicians from image acquisition to diagnosis and follow-up. Their flagship product, Nuclarity, utilizes artificial intelligence to improve the quality of PET imaging, which is critical in oncologic and neurologic diagnoses, thereby reducing patient wait times for scans and treatment. The solutions are designed to optimize processes within imaging centers, ensuring that patient safety is prioritized by minimizing radiation exposure during scans. Nuclivision serves a diverse client base that includes hospitals, imaging centers, and individual healthcare providers across multiple geographical markets, including North America, Europe, and select regions in Asia.Nuclivision generates revenue primarily through a subscription-based model for its software products, particularly Nuclarity. Healthcare providers and imaging centers enter into service agreements that include both upfront software installation fees and ongoing subscription payments for software updates and support. This model allows clients to access the latest advancements in imaging technology while ensuring continuous service and maintenance. The revenue structure also incorporates potential partnerships with healthcare organizations for collaborative usage of its technologies, enhancing diagnostic capabilities. Specific pricing details for the subscription plans and associated services are tailored to the needs of individual clients, providing a flexible approach that accommodates various operational scales.In April 2025, Nuclivision BV raised EUR 5 million in venture funding to support the launch of Nuclarity, its AI software for PET imaging. The company plans to utilize the funding for a commercial rollout and expansion efforts in Europe and the US. Upcoming products and enhancements are aimed at further improving their imaging solutions, with specific market entry strategies being developed for targeted regions. Further details on specific upcoming products and additional geographic markets are anticipated to be announced in conjunction with the rollout.

## Funding rounds

- Seed, May 7, 2025, $2.3M — Imec.xpand, HERAN Partners, LUMO Labs BV

## Investors

- Imec.xpand (https://capitalatlas.ai/funds/imec-xpand) — Seed
- HERAN Partners (https://capitalatlas.ai/funds/heran-partners) — Seed
- LUMO Labs BV (https://capitalatlas.ai/funds/lumo-labs-bv) — Seed